Sugi Predict

Sugi Predict / Compounds / SCHEMBL2943467

SCHEMBL2943467

SCHEMBL2943467

Clc1ccc2ncc(I)n2n1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 4/20 0.53
▸ DYRK1A Q13627 10/20 0.49
▸ DYRK2 Q92630 10/20 0.49
▸ DYRK1B Q9Y463 9/20 0.49
▸ CDK5 Q00535 7/20 0.49
▸ CDK5R1 Q15078 7/20 0.49
▸ DYRK3 O43781 7/20 0.49
▸ CCNA2 P20248 6/20 0.49
▸ CDK2 P24941 6/20 0.49
▸ CCNT1 O60563 4/20 0.49
▸ CDK9 P50750 4/20 0.49
▸ KDM4E B2RXH2 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ MKNK1 Q9BUB5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3452842 0.79 TNF (0.56) TNFDYRK1ADYRK2DYRK1BCDK5
SCHEMBL20903423 0.76 MEN1 (0.44) TNFKDM4EALDH1A1SMN1; SMN2MKNK1
SCHEMBL10246682 0.76 TNF (0.57) TNFDYRK1ADYRK2DYRK1BCDK5
SCHEMBL102527 0.76 TNF (0.53) TNFDYRK1ADYRK2DYRK1BCDK5
SCHEMBL9216298 0.76 TNF (0.53) TNFDYRK1ADYRK2DYRK1BCDK5
SCHEMBL10245157 0.76 TNF (0.57) TNFDYRK1ADYRK2DYRK1BCDK5
SCHEMBL17447667 0.76 FYN (0.35) DYRK1ADYRK2DYRK1BCDK5CDK5R1
SCHEMBL15254368 0.76 TNF (0.49) TNFDYRK1ADYRK2DYRK1BCDK5
SCHEMBL22185649 0.76 TNF (0.49) TNFDYRK1ADYRK2DYRK1BCDK5
SCHEMBL22159024 0.73 TNF (0.50) TNFDYRK1ADYRK2DYRK1BCDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304582-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORPORATION 2025-10-02 — — US disclosed
EP-4616913-A2 GCN2 INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2025-09-17 — — EP disclosed
EP-3746075-B1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-09-03 — — EP disclosed
EP-3321268-B1 BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY SCIENCE TECH & RES (SG) 2025-06-04 — — EP disclosed
CN-120025336-A LIN28 inhibitors and methods of use thereof 加利福尼亚大学董事会 2025-05-23 — — CN disclosed
CN-115087657-B LIN28 inhibitors and methods of use thereof 加利福尼亚大学董事会 2025-01-21 — — CN disclosed
CN-114989176-B Imidazopyridazine derivative and application thereof 深圳市新樾生物科技有限公司 2024-08-27 — — CN disclosed
CN-118005640-A GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-05-10 — — CN disclosed
US-20240124469-A1 PIM KINASE INHIBITOR HANGZHOU BIOSUN PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 — — US disclosed
CN-117624166-A Triazole derivative and preparation method and application thereof 苏州朗睿生物医药有限公司 2024-03-01 — — CN disclosed
WO-2013034048-A1 SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2013-03-14 — — WO disclosed
US-20100216798-A1 FUSED HETEROCYCLES AS LCK INHIBITORS ASTELLAS PHARMA INC (JP) 2010-08-26 — — US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 — — US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 — — US disclosed
EP-2176266-A2 SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES AS KINASE INHIBITORS, THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS Bayer Schering Pharma Aktiengesellschaft (DE) 2010-04-21 — — EP disclosed
EP-1910369-A1 FUSED HETEROCYCLES AS LCK INHIBITORS Astellas Pharma Inc. (JP) 2008-04-16 — — EP disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 — — US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 — — US disclosed
WO-2007025540-A2 SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES AS KINASE INHIBITORS, THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-08 — — WO disclosed
WO-2007013673-A1 FUSED HETEROCYCLES AS LCK INHIBITORS ASTELLAS PHARMA INC. (JP) 2007-02-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304582-A1 Bicyclic Ureas As Kinase Inhibitors JAK2, UCK2, ULK2 TNF 4319/4885DYRK1A 547/4885DYRK2 383/4885
US-20240124469-A1 PIM KINASE INHIBITOR PIM1, PIM2, PIM3 TNF 2161/4885DYRK1A 500/4885DYRK2 403/4885
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 TNF 3662/4885DYRK1A 461/4885DYRK2 336/4885
US-20100216798-A1 FUSED HETEROCYCLES AS LCK INHIBITORS LCK, ZAP70, FYN TNF 4285/4885DYRK1A 363/4885DYRK2 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.